Back to results
US 2024/0262804 A1Published application
Nitrogen-containing heterocyclic ketones, preparation methods and medicinal uses thereof
AssigneesHansoh Bio LLC, Shanghai Hansoh Biomedical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
InventorsHugh Y. Zhu, Gang Liu, Che Liu
Life of this patent
Estimating the term…
Abstract
Provided herein is novel N-heterocyclic ketones that are useful for treatment of hypertrophic cardiomyopathy (HCM) and other heart diseases. The preparation method thereof, pharmaceutical compositions comprising the compound.
Claims20
A compound of formula (I):
- or a tautomer, cis- or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
- A is selected from the group consisting of:
- R is —(CR1R2)nR3;
- R1 and R2 are independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
- n is 0, 1, 2, 3 or 4;
- R3 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein each of alkyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl at each occurrence is independently unsubstituted or substituted with one or more substituents selected from the R3 group consisting of deuterium, halogen, amino, nitro, oxo, cyano, hydroxy, alkyl, alkoxy, haloalkyl, hydroxyalkyl, —NRaRb, —C(O)Ra, —C(O)NRaRb, —C(O)ORa, —OC(O)Ra, —S(O)mRa, —S(O)mNRaRb, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl in said R3 group of substituents is independently unsubstituted or substituted with one or more substituents selected from alkyl, haloalkyl, cyano, —C(O)Ra, halogen, and cycloalkyl;
- m is 0, 1 or 2;
- R′ is selected from the group consisting of alkyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein each of alkyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl at each occurrence is independently unsubstituted or substituted with one or more substituents selected from the group consisting of deuterium, halogen, amino, cyano, hydroxy, alkyl, alkoxy, haloalkyl, hydroxyalkyl, —NRcRd, —C(O)Rc, —C(O)NRcRd, —C(O)ORc, —OC(O)Rc,
- —S(O)mRc and —S(O)mNRcRd;
- Ra, Rb, Rc, and Rd are independently selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, alkyl, alkoxy, haloalkyl and hydroxyalkyl.
7 more elements
A compound selected from the group consisting of:
- tautomer, cis- or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt solvate, or prodrug thereof.
Dependencies are inferred from the claim text.